AR and prostate carcinoma: Meanwhile, TMPRSS2-ERG rearrangements and AR or MYC amplifications, present in the tumors of 6 out of the aforementioned 26 patients, were exclusively identified by the Medicover Genetic’s prostate cancer assay, since such structural variants are not targeted by the Ampliseq IAD207308_231 panel.